BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 18207572)

  • 1. Polymorphisms in transporter and phase II metabolism genes as potential modifiers of the predisposition to and treatment outcome of de novo acute myeloid leukemia in Israeli ethnic groups.
    Müller P; Asher N; Heled M; Cohen SB; Risch A; Rund D
    Leuk Res; 2008 Jun; 32(6):919-29. PubMed ID: 18207572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polymorphisms in ABCG2, ABCC3 and CNT1 genes and their possible impact on chemotherapy outcome of lung cancer patients.
    Müller PJ; Dally H; Klappenecker CN; Edler L; Jäger B; Gerst M; Spiegelhalder B; Tuengerthal S; Fischer JR; Drings P; Bartsch H; Risch A
    Int J Cancer; 2009 Apr; 124(7):1669-74. PubMed ID: 19107936
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The effects of glutathione S-transferase (GSTT1 and GSTM1) genes polymorphisms on treatment efficacy and prognosis of acute myeloid leukemia].
    Zhang Y; Yang L; Li R; Zhang L; Zhang MR; Xiao ZJ
    Zhonghua Nei Ke Za Zhi; 2006 Mar; 45(3):213-6. PubMed ID: 16624155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of cytochrome P450, glutathione S-transferase and N-acetyl transferase 2 gene polymorphisms with incidence of acute myeloid leukemia.
    Majumdar S; Mondal BC; Ghosh M; Dey S; Mukhopadhyay A; Chandra S; Dasgupta UB
    Eur J Cancer Prev; 2008 Apr; 17(2):125-32. PubMed ID: 18287869
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MRP3, BCRP, and P-glycoprotein activities are prognostic factors in adult acute myeloid leukemia.
    Benderra Z; Faussat AM; Sayada L; Perrot JY; Tang R; Chaoui D; Morjani H; Marzac C; Marie JP; Legrand O
    Clin Cancer Res; 2005 Nov; 11(21):7764-72. PubMed ID: 16278398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of XPC, XPD, XPF, and XPG gene polymorphisms on the risk and the outcome of acute myeloid leukemia in a Romanian population.
    Bănescu C; Iancu M; Trifa AP; Dobreanu M; Moldovan VG; Duicu C; Tripon F; Crauciuc A; Skypnyk C; Bogliș A; Lazar E
    Tumour Biol; 2016 Jul; 37(7):9357-66. PubMed ID: 26779634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polymorphisms of the drug transporters ABCB1, ABCG2, ABCC2 and ABCC3 and their impact on drug bioavailability and clinical relevance.
    Bruhn O; Cascorbi I
    Expert Opin Drug Metab Toxicol; 2014 Oct; 10(10):1337-54. PubMed ID: 25162314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Genetic polymorphism in GST, NAT2, and MTRR and susceptibility to childhood acute leukemia].
    Gra OA; Glotov AS; Kozhekbaeva Zhm; Makarova OV; Nasedkina TV
    Mol Biol (Mosk); 2008; 42(2):214-25. PubMed ID: 18610829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of glutathione S-transferase, EPHX, and p53 codon 72 gene polymorphisms with adult acute myeloid leukemia.
    Chauhan PS; Ihsan R; Yadav DS; Mishra AK; Bhushan B; Soni A; Kaushal M; Devi TR; Saluja S; Gupta DK; Mittal V; Saxena S; Kapur S
    DNA Cell Biol; 2011 Jan; 30(1):39-46. PubMed ID: 20731606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BCRP mRNA expression v. clinical outcome in 40 adult AML patients.
    Uggla B; Ståhl E; Wågsäter D; Paul C; Karlsson MG; Sirsjö A; Tidefelt U
    Leuk Res; 2005 Feb; 29(2):141-6. PubMed ID: 15607361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ATP-binding casette transporter expression in acute myeloid leukemia: association with in vitro cytotoxicity and prognostic markers.
    Varatharajan S; Abraham A; Karathedath S; Ganesan S; Lakshmi KM; Arthur N; Srivastava VM; George B; Srivastava A; Mathews V; Balasubramanian P
    Pharmacogenomics; 2017 Feb; 18(3):235-244. PubMed ID: 28112576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of BCRP and MDR-1 co-expression by quantitative molecular assessment in AML patients.
    Galimberti S; Guerrini F; Palumbo GA; Consoli U; Fazzi R; Morabito F; Santini V; Petrini M
    Leuk Res; 2004 Apr; 28(4):367-72. PubMed ID: 15109536
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Instability of mRNA expression signatures of drug transporters in chronic myeloid leukemia patients resistant to imatinib.
    Gromicho M; Magalhães M; Torres F; Dinis J; Fernandes AR; Rendeiro P; Tavares P; Laires A; Rueff J; Sebastião Rodrigues A
    Oncol Rep; 2013 Feb; 29(2):741-50. PubMed ID: 23229016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polymorphisms in GSTT1, GSTM1, NAT1 and NAT2 genes and bladder cancer risk in men and women.
    McGrath M; Michaud D; De Vivo I
    BMC Cancer; 2006 Oct; 6():239. PubMed ID: 17026750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Study on the relationship between polymorphisms of Cyp1A1, GSTM1, GSTT1 genes and the susceptibility to acute leukemia in the general population of Hunan province].
    Liu QX; Chen HC; Liu XF; Cao YF; Zhang J; Liu J
    Zhonghua Liu Xing Bing Xue Za Zhi; 2005 Dec; 26(12):975-9. PubMed ID: 16676594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ABCC3 and GSTM5 gene polymorphisms affect overall survival in Polish acute myeloid leukaemia patients.
    Butrym A; Łacina P; Bogunia-Kubik K; Mazur G
    Curr Probl Cancer; 2021 Oct; 45(5):100729. PubMed ID: 33714589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polymorphisms of glutathione-S-transferase and arylamine N-acetyltransferase enzymes and susceptibility to colorectal cancer.
    Kiss I; Németh A; Bogner B; Pajkos G; Orsós Z; Sándor J; Csejtey A; Faluhelyi Z; Rodler I; Ember I
    Anticancer Res; 2004; 24(6):3965-70. PubMed ID: 15736440
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of the drug transporters MDR1/ABCB1, MRP1/ABCC1, MRP2/ABCC2, BCRP/ABCG2, and PXR in peripheral blood mononuclear cells and their relationship with the expression in intestine and liver.
    Albermann N; Schmitz-Winnenthal FH; Z'graggen K; Volk C; Hoffmann MM; Haefeli WE; Weiss J
    Biochem Pharmacol; 2005 Sep; 70(6):949-58. PubMed ID: 16054595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Arylamine N-acetyltransferase 1 (NAT1) and 2 (NAT2) polymorphisms in susceptibility to bladder cancer: the influence of smoking.
    Okkels H; Sigsgaard T; Wolf H; Autrup H
    Cancer Epidemiol Biomarkers Prev; 1997 Apr; 6(4):225-31. PubMed ID: 9107426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacogenetic characterization of sulfasalazine disposition based on NAT2 and ABCG2 (BCRP) gene polymorphisms in humans.
    Yamasaki Y; Ieiri I; Kusuhara H; Sasaki T; Kimura M; Tabuchi H; Ando Y; Irie S; Ware J; Nakai Y; Higuchi S; Sugiyama Y
    Clin Pharmacol Ther; 2008 Jul; 84(1):95-103. PubMed ID: 18167504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.